|
¾È°ú °ü·Ã ±â¾÷ °è¾à µ¿Çâ Á¶»ç : ÀμöÇÕº´, ±ÝÀ¶, »ç¾÷ ¹× ±â¼ú ÆÇ¸Å
2018/2019 Ophthalmic Deals Book: Mergers and Acquisitions, Financing, and Business/Technology Sales
|
¸®¼Ä¡»ç |
Market Scope, LLC
|
¹ßÇàÀÏ |
2019³â 12¿ù |
»óǰ ÄÚµå |
644816 |
ÆäÀÌÁö Á¤º¸ |
¿µ¹® |
°¡°Ý |
|
¾È°ú °ü·Ã ±â¾÷ °è¾à µ¿Çâ Á¶»ç : ÀμöÇÕº´, ±ÝÀ¶, »ç¾÷ ¹× ±â¼ú ÆÇ¸Å
2018/2019 Ophthalmic Deals Book: Mergers and Acquisitions, Financing, and Business/Technology Sales
|
¹ßÇàÀÏ : 2019³â 12¿ù | ÆäÀÌÁö Á¤º¸ : ¿µ¹® |
|
|
¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
2018³â°ú 2019³â¿¡ ÇàÇØÁø ¾È°ú °ü·Ã ±â¾÷ÀÇ ÀÚº»°Å·¡ 108°Ç¿¡ ´ëÇØ ´Ù·ç¾úÀ¸¸ç, À̰Ϳ¡´Â º¥Ã³Ä³ÇÇÅÐ, »ç¸ð, °ø¸ð ÁõÀÚ¿¡ ÀÇÇÑ ÅõÀÚ¿Í ±â¾÷ ¸Å°¢ÀÌ Æ÷ÇԵ˴ϴÙ. º» Á¶»ç º¸°í¼´Â ¾È°ú °ü·Ã ½ÃÀå °¢ ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼® µî ¸¹Àº »õ·Î¿î Ư¡À» °®Ãß°í ÀÖÀ¸¸ç, ºÎ¹®º° °Å·¡ °Ç¼ö¿Í Àüü °Ç¼ö, ´Ù¸¥ ºÎ¹®°ú ºñ±³ÇÑ ¹èºÐ, ¿ëµµº°¡¤Á¾·ùº° ÀÚ±Ý, °¢ ºÎ¹®¿¡¼ °¡Àå ¸¹Àº ÀÚ±ÝÀ» ¸ðÀº ±â¾÷¿¡ ´ëÇØ ºÐ¼®Çß½À´Ï´Ù.
¶ÇÇÑ ¾È°ú ¿µ¿ª¿¡ ´ëÇÑ ±¹¸³º¸°Ç¿ø(NIH) µîÀÇ ¿¬±¸ º¸Á¶±Ý¿¡ ´ëÇÑ ºÐ¼®µµ Æ÷ÇԵǾî ÀÖÀ¸¸ç, ÇöÀç °³¹ßµÇ°í ÀÖ´Â ¸Á¸·Áúȯ¿¡ ´ëÇÑ À¯ÀüÀÚ Ä¡·á ¸®½ºÆ®, 57°³ µµÇ¥°¡ »õ·Ó°Ô Ãß°¡µÇ¾î ÀÖ½À´Ï´Ù.
2018/2019³âÆÇ º¸°í¼ÀÇ Æ¯Â¡
¾È°ú ¿µ¿ª¿¡ ´ëÇÑ ÅõÀÚ¿¡ ´ëÇØ ºÐ¼®Çß½À´Ï´Ù. °¢Á¾ ±â¼úÀÇ ½ÃÀå °¡Ä¡¸¦ Æò°¡Çϱâ À§ÇÑ Á¤º¸¸¦ Á¦°øÇϸç, ¾È°ú °ü·Ã »õ·Î¿î º¥Ã³¿¡ ´ëÇÑ ÅõÀÚ ¹× °Å·¡·®À» ¹ÙÅÁÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. º¸°í¼¿¡´Â º¥Ã³ ijÇÇÅÐ, °ø¸ð, ¶óÀ̼±½º, ¸ñÇ¥ ´Þ¼º Æ÷»ó±Ý, Á¦Ç° ¹× ±â¾÷ ¸Å°¢, ÁÖ¿ä Â÷ÀÔ±Ý µî 2018³â°ú 2019³â 1-10¿ù°£ ÇàÇØÁø ¾È°ú °ü·Ã º¥Ã³ ÅõÀÚ Á¤º¸°¡ ´ã°Ü ÀÖ½À´Ï´Ù.
- ÀÚ±Ý ¿ëµµº° ÀÚº»°Å·¡ ºÐ·ù : ½Å±Ô º¥Ã³, »ó¾÷ ÀÚº», ±â¾÷ ÆÇ¸Å, ¶óÀ̼±½º ºñ¿ë ÁöºÒ
- 4°¡Áö ÅõÀÚ ÇüÅ ºÐ¼® : Àü·«Àû ÅõÀÚÀÚ, º¥Ã³ ijÇÇÅÐ, °ø¸ð, »ç¸ð
- ¾È°ú °ü·Ã 7°³ ºÎ¹®¿¡¼ÀÇ °Å·¡¿¡ °üÇÑ »ó¼¼ÇÑ ºÐ¼® : ¾È±¸, ¸Á¸·, ³ì³»Àå, ¹é³»Àå, Áø´Ü, °¢¸·, ±¼Àý ±â´É, °¢ ºÎ¹®¿¡¼ÀÇ ÁÖ¿ä ÅõÀÚÀÚ¿Í °Å·¡
- ÀÚº»°Å·¡ÀÇ ÁÖ¿ä ÁöÇ¥ : ÀÚ±ÝÀ» Á¶´ÞÇϰí ÀÖ´Â ±â¾÷ ÅõÀÚ¸¦ ½Ç½ÃÇϰí ÀÖ´Â ±â¾÷, °¡Àå ¸¹Àº ÀÚ±ÝÀ» ¸ðÀº ±â¾÷¿¡ °üÇÑ ÁöÇ¥
- º» º¸°í¼¿¡¼ ´Ù·é ±â¾÷ : 78°³ ±â¾÷°ú Á¶´ÞÇÑ ÀÚ±Ý ÃÑ¾× ¹× °è¾à ±Ô¸ð Áß¾Ó°ª ÀÌ»óÀÇ ÀÚ±ÝÀ» Á¶´ÞÇÑ ±â¾÷ 46°³»çÀÇ ±â¾÷ °³¿ä
LSH 20.03.18
Our 2018/2019 Ophthalmic Deals Book covers 108 ophthalmic company transactions in 2018 and 2019, including investments by venture capital firms, private equity, public stock offerings, and sales of companies. There are many new features in the 2019 version of this report, including a detailed analysis of each ophthalmic sector. This analysis reviews sector transaction counts and totals, sector allocation compared with other ophthalmic sectors, sector funds by use and type, and the top funded companies in each sector.
Also new in the 2019 version is an analysis of NIH and other grants to ophthalmology. A comprehensive list of retinal disease gene therapies in development and an additional 57 tables and figures are also new in 2019.
What's New
Our 2018/2019 Ophthalmic Deals Book covers 108 ophthalmic company transactions in 2018 and 2019, including investments by venture capital firms, private equity, public stock offerings, and sales of companies. There are many new features in the 2019 version of this report, including a detailed analysis of each ophthalmic sector. This analysis reviews sector transaction counts and totals, sector allocation compared with other ophthalmic sectors, sector funds by use and type, and the top funded companies in each sector.
Market Scope's "2018/20198 Ophthalmic Deals Book" analyzes investments in ophthalmology and provides information for evaluation of the market value of various technologies, as evidenced by investment amounts and sales prices for new ophthalmic ventures. The information covers investments in ophthalmic ventures in 2018 and the first 10 months of 2019, including venture capital, public offerings, licensing, milestone payments, sales of products and companies, and major borrowings. Also included:
- Transactions categorized by fund use: new venture, commercial equity, sale of companies, and license payments.
- Four investment types are analyzed in this report: strategic investors, venture capital, public offerings, and private equity.
- Detailed transaction analysis provided for seven ophthalmic sectors: dry eye, retina, glaucoma, cataract, diagnostic, cornea, and refractive. Key investors and transactions in each sector are included.
- Key metrics in this report include: companies raising funds, companies making investments, and top funded companies.
- Company coverage: 78 companies, along with total funds earned, are included in the report; company profiles are provided for 46 companies that raised greater than the median deal size.
Also new in the 2019 version is an analysis of NIH and other grants to ophthalmology. A comprehensive list of retinal disease gene therapies in development and an additional 57 tables and figures are also new in 2019.
|

|
¾È°ú¿ë ¿µ»ó Àåºñ ½ÃÀå : ÀλçÀÌÆ®, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(-2025³â)
¾È°ú¿ë Á¡¾×ź¼º¹°Áú(OVD) ½ÃÀå : ÀλçÀÌÆ®, °æÀï ±¸µµ¿Í ½ÃÀå ¿¹Ãø(-2025³â)
¾È°ú¿ë ÆèÅäÃÊ ·¹ÀÌÀú ½ÃÀå : ÀλçÀÌÆ®, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(-2025³â)
¼¼°èÀÇ ¾È°ú¿ë Áø´Ü ¹× ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ±âȸ¿Í Àü·«(-2030³â) : COVID-19¿¡ ÀÇÇÑ ¿µÇâ°ú ȸº¹
¾È°ú ¼ö¼ú ±â±¸ ½ÃÀå ºÐ¼®(2020³â) : ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø(2019-2025³â)
¾È°ú¿ë ¿µ»ó Àåºñ : ÀÇ·á±â±â ÆÄÀÌÇÁ¶óÀÎ Æò°¡
¾È°ú¿ë Áø´Ü Àåºñ : ÀÇ·á±â±â ÆÄÀÌÇÁ¶óÀÎ Æò°¡
À¯·´ 5°³±¹ÀÇ ¾È°ú ½ÃÀå : Áö¿ª ºÐ¼®(2019-2025³â)
¼¼°èÀÇ ¾È°ú¿ë ±â±â ½ÃÀå : ÇöȲ ºÐ¼® ¹× ÇâÈÄ Àü¸Á(2020-2026³â)
¼¼°èÀÇ ¾È°ú¿ë È®´ë°æ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®, ºÎ¹®º° ¿¹Ãø(È®´ë°æ Á¾·ùº°(°¥¸±·¹ÀÌÇü, ÇÁ¸®ÁòÇü), È®´ë°æ Çü»óº°, ÃÖÁ¾ ¿ëµµº°(º´¿ø, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ), Áö¿ªº°)
|